This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry the full length fusion (F) protein of Human respiratory syncytial virus (RSV) isolate A2 strain (UniProtKB/Swiss-Prot: P03420.1, with prefusion-stabilizing mutations). RSV is a respiratory virus with fusion (F) protein as the major target of neutralizing antibodies/vaccine-elicited sera.

• Anti-RSV neutralizing antibody screening at high throughput
• Anti-RSV drug screening at high throughput
• RSV vaccine efficacy evaluation at high throughput
• RSV pseudovirus transduction of target cells for viral entry, receptor recognition, cellular tropism and functional studies, such as ADCC analysis

As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. Titration result showing that the starting 2-fold diluted pseudovirus generates signal ~10000-fold higher than uninfected control (cell alone as background in blue). Three known neutralizing mAbs (D25, 101F, and MPE8) were used to validate its neutralizing activity against this pseudovirus.

A complete protocol is supplied with the shipping of product. Briefly, incubate 50 μl diluted virus with sample in each well of 96-well plate for 60 min at 37 °C. Then add 50 μl target cells, such as HEp-2, Vero, or others expressing RSV receptor, followed by luciferase signal reading.

Note: Pseudoviruses are intended for research use only. A positive control mAb is included with pseudovirus purchase.